A hypotensive effect of corinfar and its effect on the indices of the central and peripheral hemodynamics were studied in 50 patients with stage II hypertension. In 3 weeks BP was lowered at the expense of a considerable decrease in the total peripheral vascular resistance (TPVR) (by 29.6%) and regional vascular resistance (by 48%). It was accompanied by an increase in the peripheral blood flow (by 61%), a reflex activation of the sympathetic-adrenal system with an increase in heart rate and cardiac output (by 22%, p less than 0.001). An index of vein distensibility remained unchanged. The addition of propranolol removed signs of the sympathetic stimulation of the cardiac activity, improved vasodilatator tolerance, enhanced a hypotensive effect of corinfar causing a transient increase in TPVR and tension of the resistive vessels only. By the end of the 4th month of therapy these indices significantly decreased. A prolonged combined therapy with corinfar and propranolol resulted in a significant decrease in the resistance of resistive vessels in maximum vasodilatation characterizing the regression of arteriole structural changes. Besides there was a decrease in the wall thickness (p less than 0.01) and left ventricular myocardial mass (by 7.88 +/- 2.66 g, p less than 0.05) that was interpreted as a tendency to a decrease in a degree of hypertrophy of the left ventricle. The efficacy of corinfar therapy was higher in the patients with hypertension with a high initial tension of the peripheral vessels.

Download full-text PDF

Source

Publication Analysis

Top Keywords

hypotensive corinfar
8
vascular resistance
8
resistive vessels
8
[treatment hypertension
4
hypertension calcium
4
calcium antagonist
4
antagonist korinfar
4
korinfar combination
4
combination obzidan]
4
obzidan] hypotensive
4

Similar Publications

Objective: In the puerperium, women with hypertensive disease of pregnancy remain at risk for maternal complications. The antihypertensive agent prescribed antepartum is usually continued postpartum; however, evidence regarding the most effective treatment is lacking. Therefore, we aimed to investigate which antihypertensive agent results in optimal treatment (both effectiveness and safety) of postpartum hypertension.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates factors affecting the long-term pulse pressure of hypertensive patients at Assosa General Hospital in Ethiopia over a two-year period.
  • Among the 325 patients, key factors influencing pulse pressure included age, residence, family history of hypertension, diabetes, chronic kidney disease, smoking status, and the stage of hypertension.
  • Findings suggest that while certain treatments and longer follow-up time help reduce pulse pressure, other risk factors need to be managed to improve health outcomes in hypertensive patients.
View Article and Find Full Text PDF

Introduction: Hypertension is a worldwide problem that affects people of all ethnicities and social groups. Its mortality rate has been steadily increasing. However, several pharmacological compounds have been used to manage hypertension and related issues.

View Article and Find Full Text PDF

Using our recently developed laser speckle contrast imaging (LSCI) to visualize blood vessels and monitor blood flow noninvasively, we test the utility of the developing chick heart as a functional model for drug screening. To this end, we examined the effects of antihypertensive agents Nifedipine and Amlodipine, belonging to the L-type calcium channel antagonist family, on blood flow visualized noninvasively through the intact shell. Guided by the live view mode, the drugs were injected through the shell and ventral to HH16-19 chick embryos.

View Article and Find Full Text PDF

Background: Postpartum hypertension is an increasingly prevalent problem and optimizing its treatment is imperative in reducing maternal morbidity and improving long-term health outcomes. Despite this, data on treatment of postpartum hypertension is limited. While most available studies focus on labetalol and nifedipine ER, these medications are not frequently used for hypertension treatment in the non-obstetric setting.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!